General Hospital Psychiatry
Volume 20, Issue 6 , Pages 339-344 , November 1998

Fluvoxamine for somatoform disorders: an open trial

  • Russell Noyes Jr., M.D.

      Affiliations

    • Department of Psychiatry, University of Iowa College of Medicine, Iowa City, USA (Dr. Noyes, Ms. Happel, Dr. Holt, Dr. Kathol, Dr. Amos, and Ms. Sieren)
    • Corresponding Author InformationAddress reprints to: Russell Noyes, Jr., M.D., Psychiatry Research, Medical Education Building, Iowa City, IA 52242-1000
    • ,
  • Rachel L. Happel (B.S.N.)

      Affiliations

    • Department of Psychiatry, University of Iowa College of Medicine, Iowa City, USA (Dr. Noyes, Ms. Happel, Dr. Holt, Dr. Kathol, Dr. Amos, and Ms. Sieren)
    • ,
  • Barbara A. Muller, M.D.

      Affiliations

    • Department of Internal Medicine, University of Iowa College of Medicine, Iowa City, USA (Drs. Muller and Kathol)
    • ,
  • Craig S. Holt, Ph.D.

      Affiliations

    • Department of Psychiatry, University of Iowa College of Medicine, Iowa City, USA (Dr. Noyes, Ms. Happel, Dr. Holt, Dr. Kathol, Dr. Amos, and Ms. Sieren)
    • ,
  • Roger G. Kathol, M.D.

      Affiliations

    • Department of Psychiatry, University of Iowa College of Medicine, Iowa City, USA (Dr. Noyes, Ms. Happel, Dr. Holt, Dr. Kathol, Dr. Amos, and Ms. Sieren)
    • Department of Internal Medicine, University of Iowa College of Medicine, Iowa City, USA (Drs. Muller and Kathol)
    • ,
  • Lori R. Sieren (B.S.N.)

      Affiliations

    • Department of Psychiatry, University of Iowa College of Medicine, Iowa City, USA (Dr. Noyes, Ms. Happel, Dr. Holt, Dr. Kathol, Dr. Amos, and Ms. Sieren)
    • ,
  • James J. Amos, M.D.

      Affiliations

    • Department of Psychiatry, University of Iowa College of Medicine, Iowa City, USA (Dr. Noyes, Ms. Happel, Dr. Holt, Dr. Kathol, Dr. Amos, and Ms. Sieren)

References 

  1. Kirmayer LJ, Robbins JM. Three forms of somatization in primary care (Prevalence, co-occurrence, and sociodemographic characteristics). J Nerv Ment Dis. 1991;179:647–655
  2. Lipowski ZJ. Somatization (The concept and its clinical application). Am J Psychiatry. 1988;145:1358–1368
  3. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, American Psychiatric Association, Washington, D.C., 1994
  4. Noyes R, Holt CS, Kathol RG. Somatization (Diagnosis and management). Arch Fam Med. 1995;4:790–795
  5. Noyes R, Kathol R, Fisher M, et al.  The validity of DSM-III-R hypochondriasis. Arch Gen Psychiatry. 1993;50:961–970
  6. Kellner R. Treatment approaches to somatizing and hypochondriacal patients. In:  Kirmayer LJ,  Robbins JM editor. Current concepts of Somatization (Research and Clinical Perspectives). Washington DC: American Psychiatric Press; 1991;p. 159–179
  7. Ward NG, Bloom VL, Friedel RO. The effectiveness of tricyclic antidepressants in the treatment of coexisting pain and depression. Pain. 1979;7:331–341
  8. Onghena P, Van Houdenhove B. Antidepressant-induced analgesia in chronic non-malignant pain (A meta-analysis of 39 placebo-controlled studies). Pain. 1992;49:205–219
  9. Smith GR. The epidemiology and treatment of depression when it coexists with somatoform disorders, somatization, or pain. Gen Hosp Psychiatry. 1992;14:265–272
  10. Kroenke K, Spitzer RL, Williams JB. Physical symptoms in primary care (Predictors of psychiatric disorder and functional impairment). Arch Fam Med. 1994;3:774–779
  11. Hamilton J, Campos R, Creed F. Anxiety, depression and management of medically unexplained symptoms in medical clinics. J Roy Col Physicians London. 1996;30:18–20
  12. Volz H-P, Stieglitz R-D, Menges K, Moller H-J. Somatoform disorders—diagnostic concept, controlled clinical trials, and methodological issues. Pharmacopsychiat. 1994;27:231–237
  13. Escobar JI. Pharmacological treatment of somatization/hypochondriasis (Overview of somatization: Diagnosis, epidemiology, and management). Psychopharmacol Bull. 1996;32:589–596
  14. Kellner R. Psychosomatic Syndromes and Somatic Symptoms. Washington, DC: American Psychiatric Press; 1991;
  15. Gruber AJ, Hudson JI, Pope HG. The management of treatment-resistant depression in disorders on the interface of psychiatry and medicine. Psychiatr Clin N Amer. 1996;19:351–369
  16. Klein KB. Controlled treatment trials in irritable bowel syndrome (A critique). Gastroenterology. 1988;95:232–241
  17. Goodnick PJ, Sandoval R. Psychotropic treatment of chronic fatigue syndrome and related disorders. J Clin Psychiatry. 1993;54:13–20
  18. Natelson BH, Cheu J, Pareja J, et al.  Randomized, double-blind, controlled placebo-phase in trial of low dose phenelzine in the chronic fatigue syndrome. Psychopharmacol. 1996;124:226–230
  19. White KP, Harth M. An analytical review of 24 controlled clinical trials for fibromyalgia syndrome (FMS). Pain. 1996;64:211–219
  20. Vercoulen JHMM, Swanink CMA, Zitman FG, Vreden SGS, Hoofs MPE, Fennis JFM, et al. Randomized, double-blind, placebo-controlled study of fluoxetine in chronic fatigue syndrome. Lancet. 1996;347:858–861
  21. Goldberg D, Mayskiy M, Mossey C, et al.  A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis Rheum. 1996;39:1852–1859
  22. Lindsay PG, Wyckoff M. The depression-pain syndrome and its response to antidepressants. Psychosomatics. 1981;22:571–577
  23. Stimmel GL, Escobar JI. Antidepressants in chronic pain (A review of efficacy). Pharmacotherapy. 1986;6:262–267
  24. Walker EA, Roy-Byrne PP, Katon WJ, et al.  An open trial of nortriptyline in women with chronic pelvic pain. Int J Psychiatry Med. 1991;21:245–252
  25. Zitman FG, Linssen ACG, Edelbroek PM, et al.  Does addition of low-dose flupenthixol enhance the analgesic effects of low-dose amitriptyline in somatoform pain disorder?. Pain. 1991;47:25–30
  26. Max MB, Lynch SA, Muir J, et al.  Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med. 1992;326:1250–1256
  27. Krishnan KRR. Monoamine oxidase inhibitors. In:  Schatzberg AF,  Nemeroff CB editor. Textbook of Psychopharmacology. Washington DC: American Psychiatric Press; 1995;p. 186–187
  28. Tollefson GD. Selective serotonin reuptake inhibitors. In:  Schatzberg AF,  Nemeroff CB editor. Textbook of Psychopharmacology. Washington DC: American Psychiatric Press; 1995;p. 171
  29. Hollyman JA, Freeling P, Pakel ES, Bhat A, Sedgwick P. Double-blind placebo-controlled trial of amitriptyline among depressed patients in general practice. J Roy Col Gen Pract. 1988;38:393–397
  30. Fallon BA, Liebowitz MR, Salman E, et al.  Fluoxetine for hypochondriacal patients without major depression. J Clin Psychopharmacol. 1993;13:438–441
  31. Fallon BA, Schneier FR, Marshall R, et al.  The pharmacotherapy of hypochondriasis. Psychopharmacol Bull. 1996;32:607–611
  32. Wesner RB, Noyes R. Imipramine an effective treatment for illness phobia. J Affect Dis. 1991;22:43–48
  33. Spitzer RL, Williams JBW, Kroenke K, et al.  Utility of a new procedure for diagnosing mental disorders in primary care (The PRIME-MD 1000 Study). JAMA. 1994;272:1749–1756
  34. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV Axis I Disorders—Patient Edition, Biometrics Research Department. New York, NY: New York State Psychiatric Institute; 1995;
  35. Ballenger JC, Burrows GD, DuPont RL, et al.  Alprazolam in panic disorder and agoraphobia (Results from a multicenter trial). Arch Gen Psychiatry. 1988;45:403–422
  36. Guy W: ECDEU Assessment Manual for Psychopharmacology, Revised Edition. Department of Health, Education, and Welfare, National Institute of Mental Health, Publication No. ADM76-338, Rockville, MD, 1976
  37. Sheehan DV. The Anxiety Disease and How to Overcome It. New York: Scribner; 1983;
  38. Derogatis LR: Brief Symptom Inventory: Administration, Scoring, and Procedures Manual, Third Edition, National Computer Systems, Minneapolis, MN, 1993
  39. Ware JE, Snow KK, Kosinski M, Gandek C. SF-12 Health Survey (Manual and Interpretation Guide). Boston, MA: The Health Institute, New England Medical Center; 1995;
  40. Quitkin FM, McGrath PJ, Stewart JW, Taylor BP, Klein DF. Can the effects of antidepressants be observed in the first two weeks of treatment. Neuropsychopharmacology. 1996;15:390–394
  41. Speckens AEM, van Hemert AM, Bolk JH, et al.  The acceptability of psychological treatment in patients with medically unexplained physical symptoms. J Psychosom Res. 1995;39:855–863
  42. Dworkin SF, Von Korff M, Le Resche L. Multiple pains and psychiatric disturbance. Arch Gen Psychiatry. 1990;47:239–244
  43. Brown FW, Golding JM, Smith GR. Psychiatric comorbidity in primary care somatization disorder. Psychosom Med. 1990;52:445–451
  44. Simon GE, Von Koff M. Somatization and psychiatric disorder in the NIMH Epidemiologic Catchment Area study. Am J Psychiatry. 1991;148:1494–1500
  45. Russo J, Katon W, Sullivan M, et al.  Severity of somatization and its relationship to psychiatric disorders and personality. Psychosomatics. 1994;35:546–556
  46. Von Korff M, Simon G. The relationship between pain and depression. Br J Psychiatry. 1996;168(Suppl 30):101–108
  47. Stein G. Drug treatment of the personality disorders. Br J Psychiatry. 1992;161:167–184
  48. Gitlin MJ. Pharmacotherapy and personality disorders (Conceptual framework and clinical strategies). J Clin Psychopharmacol. 1993;13:343–353
  49. Creed F, Guthrie E. Techniques for interviewing the somatizing patient. Br J Psychiatry. 1993;162:467–471
  50. Sharpe M, Peveler R, Mayou R. The psychological treatment of patients with functional somatic symptoms (A practical guide). J Psychosom Res. 1992;36:515–529

☆ This was supported by a grant from Pharmacia and Upjohn Company and Solvay Pharmaceuticals, Inc.

PII: S0163-8343(98)00044-9

General Hospital Psychiatry
Volume 20, Issue 6 , Pages 339-344 , November 1998

Article Tools